Tags: Epigenetics

blog

Combination Therapy: The Right Approach for Alzheimer’s

Combination therapy will be the most effective treatment for Alzheimer’s disease. Learn why they hold such promise and why Amylyx's drug is the first such therapy we are funding. 

announcements

Innovative Alzheimer's Combination Therapy Trial Supported by New Joint Funding Initiative

We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.

announcements

ADDF Invests $300,000 to Support Phase 2 Clinical Trial of Epigenetic Therapy

A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.

blog

Closing in on a Cure: Oryzon Genomics and ORY-2001

Discover ORY-2001, a revolutionary epigenetic therapy for Alzheimer's disease being developed by Oryzon Genomics in Barcelona, Spain. 

blog

Top Five Alzheimer’s Advances in 2016

In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.

blog

Advancing Epigenetics: A New Approach to Treating Alzheimer’s Disease

Dr. Howard Fillit discusses epigenetic treatments, one of the newest and most promising areas of our portfolio. 

announcements

Five New Grants Fund Promising Treatments & Biomarkers

The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.

announcements

Ten New Grants Support Alzheimer's Drug Discovery and Biomarker Development

The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.

blog

New Drug Targets Are Highlight of Alzheimer's Conference

Presenters at our recent conference shared exciting progress on new Alzheimer's drug targets and biomarkers.